Icosavax Quarterly Cash Flow Statements Chart
Quarterly
|
Annual
Icosavax Quarterly Cash Flow Statements Table
Quarterly
|
Annual
| Unit: USD | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 | 2022-09-30 | 2022-06-30 | 2022-03-31 | 2021-12-31 | 2021-09-30 |
|---|---|---|---|---|---|---|---|---|---|
| operating activities: | |||||||||
| net income | -22,041,000 | -26,497,000 | -24,561,000 | -23,613,000 | -21,976,000 | -22,636,000 | -23,533,000 | -18,182,000 | -34,386,000 |
| adjustments to reconcile net income to cash from operating activities: | |||||||||
| stock-based compensation | 6,602,000 | 6,311,000 | 6,000,000 | 6,158,000 | 5,434,000 | 5,552,000 | 4,550,000 | 3,677,000 | 23,670,000 |
| depreciation | 763,000 | 665,000 | 643,000 | 619,000 | 143,000 | 55,000 | 43,000 | 36,000 | 29,000 |
| non-cash lease expense | 262,000 | 281,000 | 255,000 | 185,000 | |||||
| amortization of premiums and discounts on short-term investments | -1,467,000 | -1,115,000 | -1,048,000 | -798,000 | -541,000 | ||||
| changes in operating assets and liabilities: | |||||||||
| prepaids and other current assets | -1,335,000 | -249,000 | -352,000 | 1,305,000 | -1,213,000 | 3,044,000 | -1,852,000 | 524,000 | -2,234,000 |
| right-of-use assets – operating leases | 97,000 | 91,000 | 84,000 | ||||||
| other noncurrent assets | 510,000 | -7,000 | -1,737,000 | ||||||
| accounts payable | -308,000 | 44,000 | -1,059,000 | 399,000 | -1,320,000 | -1,312,000 | 1,038,000 | 709,000 | 771,000 |
| accrued and other current liabilities | -1,423,000 | 1,892,000 | 378,000 | 2,099,000 | 1,814,000 | -2,602,000 | 2,691,000 | 2,270,000 | 1,351,000 |
| deferred revenue | 0 | 0 | 0 | -582,000 | -2,070,000 | 1,473,000 | |||
| operating lease liabilities | -370,000 | -357,000 | -527,000 | ||||||
| proceeds from lease incentive | 0 | 0 | 530,000 | 1,936,000 | 0 | ||||
| net cash from operating activities | -18,972,000 | -19,222,000 | -21,649,000 | -9,004,000 | -17,378,000 | -17,833,000 | -17,460,000 | -13,036,000 | -9,326,000 |
| capex | -32,000 | -679,000 | -1,465,000 | -4,779,000 | -3,902,000 | -2,204,000 | 102,000 | -296,000 | -151,000 |
| free cash flows | -19,004,000 | -19,901,000 | -23,114,000 | -13,783,000 | -21,280,000 | -20,037,000 | -17,358,000 | -13,332,000 | -9,477,000 |
| investing activities: | |||||||||
| purchases of property and equipment | -32,000 | -679,000 | -1,573,000 | -2,550,000 | -3,955,000 | -3,486,000 | -1,122,000 | -423,000 | -15,000 |
| purchases of short-term investments | -112,372,000 | 0 | -50,000,000 | -50,063,000 | -36,478,000 | ||||
| maturities of short-term investments | 39,750,000 | 56,501,000 | 63,600,000 | 48,500,000 | |||||
| net cash from investing activities | -72,654,000 | 55,822,000 | 12,027,000 | -6,742,000 | -26,183,000 | -135,402,000 | -1,122,000 | -423,000 | -15,000 |
| financing activities: | |||||||||
| proceeds from issuance of common stock, net of issuance costs | -269,000 | ||||||||
| proceeds from exercise of stock options | 61,000 | 321,000 | 117,000 | ||||||
| payment of deferred offering costs | |||||||||
| net cash from financing activities | -208,000 | 68,071,000 | 117,000 | 10,087,000 | -279,000 | 223,000 | 276,000 | 260,000 | 191,500,000 |
| net increase in cash, cash equivalents, and restricted cash | -91,834,000 | -5,659,000 | -43,840,000 | ||||||
| cash, cash equivalents, and restricted cash at beginning of period | 0 | 0 | 59,907,000 | 0 | 0 | ||||
| cash, cash equivalents, and restricted cash at end of period | -91,834,000 | 104,671,000 | 50,402,000 | -5,659,000 | -43,840,000 | ||||
| supplemental disclosure of noncash activities | |||||||||
| purchases of property and equipment included in accounts payable and accrued liabilities | 108,000 | -2,229,000 | 53,000 | 1,282,000 | 1,224,000 | ||||
| right-of-use assets and lease liabilities recognized upon commencement of lease | 0 | 0 | 0 | 3,370,000 | |||||
| issuance costs included in accounts payable and accrued liabilities | |||||||||
| net decrease in cash, cash equivalents, and restricted cash | -9,505,000 | ||||||||
| non-cash interest expense | 0 | 0 | |||||||
| change in fair value of embedded derivative liability | 0 | 0 | |||||||
| loss on extinguishment of convertible promissory note | 0 | 0 | |||||||
| proceeds from issuance of convertible preferred stock, net of issuance costs | 0 | 0 | |||||||
| proceeds from initial public offering, net of offering costs | 28,000 | ||||||||
| proceeds from exercise of stock options, including early exercise | 312,000 | 83,000 | 223,000 | 276,000 | 232,000 | 48,000 | |||
| conversion of preferred stock to common stock | 0 | ||||||||
| conversion of convertible note (including accrued interest) and derivative liability for series b-2 convertible preferred stock | |||||||||
| deferred offering costs included in accounts payable and accrued and other current liabilities | |||||||||
| net increase in cash and restricted cash | -18,306,000 | -13,199,000 | 182,159,000 | ||||||
| cash and restricted cash at beginning of period | 280,724,000 | 0 | 0 | ||||||
| cash and restricted cash at end of period | 262,418,000 | -13,199,000 | 182,159,000 | ||||||
| issuance costs and amounts payable for convertible preferred stock included in accounts payable and accrued liabilities | |||||||||
| numerator: | |||||||||
| denominator: | |||||||||
| weighted-average common shares outstanding, basic and diluted | 39,602,146,000 | -8,417,968,000 | 23,264,083,000 | ||||||
| less: weighted-average unvested common stock | -200,341,000 | -111,052,000 | 245,648,000 | ||||||
| weighted-average shares used for eps calculation | 39,401,805,000 | -8,529,020,000 | 23,509,731,000 | ||||||
| net income per share | -600 | -2,430 | 1,560 | ||||||
| proceeds from issuance of convertible promissory notes, net of issuance costs | |||||||||
| purchases of property and equipment included in accounts payable | 127,000 | -136,000 | |||||||
| conversion of convertible note (including accrued interest) and embedded derivative liability for series b-2 convertible preferred stock | |||||||||
| unpaid initial public offering costs |
We provide you with 20 years of cash flow statements for Icosavax stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as operating cash flows, cash levels, capital expenditures, profits, stock-based compensations and profit margins. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Icosavax stock. Explore the full financial landscape of Icosavax stock with our expertly curated income statements.
The information provided in this report about Icosavax stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.